| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441982 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Most patients and doctors judged moderate survival benefits sufficient to make ACT in NSCLC worthwhile, but the preferences of doctors varied less than those of patients. Doctors should endeavour to elicit patients' preferences during discussions about ACT in NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Prunella Blinman, Brett Hughes, Catherine Crombie, Tim Christmas, Malcolm Hudson, Anne-Sophie Veillard, Nick Muljadi, Michael Millward, Gavin Wright, Peter Flynn, Morgan Windsor, Martin Stockler, Sue-Anne McLachlan,